Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
This triple agonism strategy builds upon the remarkable clinical success of dual GLP-1/GIP agonists like tirzepatide, which have shown unprecedented weight loss efficacy, by adding a third mechanism - glucagon receptor activation - to further enhance metabolic benefits, particularly energy expenditure and hepatic fat oxidation
3 , -
Chemically, the effects may vary among different patient groups, but theres also a dopaminergic component: dopamine, a hormone released in the brain in response to stimuli, may decrease when using these peptides
The cardiovascular and renal benefits of GLP-1 drugs are real and now well documented in outcome trials, but the receptor biology behind them is more indirect than it first appears
The former Calibrate health coach suggested another factor in the startup's strategy: what insurance companies were willing to pay for
Dual GIP/GLP-1 agonists show promising cardiovascular benefits in early data, with comprehensive outcome trials currently underway
US$ 21.75
US$ 20.39
US$ 22.70
US$ 26.51
US$ 22.40
US$ 29.69
US$ 26.72
US$ 25.72
